The Cardiovascular Risk Factor Hiding in Plain Sight: What Clinicians Need to Know About Lipoprotein(a)

For decades, the cardiovascular medicine community has operated with a working assumption: control LDL cholesterol aggressively, and you've addressed the lion's share of modifiable atherosclerotic risk. Statins became the cornerstone of preventive cardiology, and for good reason — the evidence is overwhelming. But a growing body of research is forcing a reckoning with an uncomfortable truth. For a significant portion of patients, even optimally managed LDL-C leaves a residual, causal, and largely unaddressed cardiovascular risk — one encoded in their DNA from birth. That risk factor is Lipoprotein(a), or Lp(a), and it may be the most consequential cardiovascular biomarker that most clinicians still don't routinely measure.

Not Just Another Lipid Particle

To understand why Lp(a) is so clinically distinct, it helps to understand what it actually is — and what it isn't. At first glance, Lp(a) resembles LDL: it carries an apolipoprotein B-100 (apoB-100) core esterified with cholesterol and phospholipids. But that structural similarity ends at the surface. Lp(a) is uniquely defined by the covalent attachment of apolipoprotein(a) [apo(a)], a large glycoprotein linked to apoB-100 via a single disulfide bond. This apo(a) moiety is what makes Lp(a) dangerous in ways that LDL simply is not.

Apo(a) contains a series of loop structures called kringle domains — specifically, kringle IV (KIV) repeats in 10 subtypes, plus a single kringle V and a catalytically inactive protease domain. The critical variable is KIV type 2, which is repeated anywhere from 2 to more than 40 times depending on the individual. This copy number variation is the primary determinant of apo(a) isoform size — and, inversely, of plasma Lp(a) concentration. Smaller isoforms are secreted more efficiently from the liver, producing higher circulating Lp(a) levels.

Crucially, apo(a)'s structural homology to plasminogen — the body's primary clot-dissolving enzyme — is not incidental. It is the molecular basis for Lp(a)'s prothrombotic properties. And Lp(a) is also the predominant plasma carrier of oxidized phospholipids (OxPL), amplifying its pathogenic reach far beyond simple cholesterol delivery.

Three Mechanisms, One Dangerous Particle

Lp(a) harms the cardiovascular system through three convergent and mechanistically distinct pathways.

Atherogenicity: Lp(a) penetrates the arterial intima, where its OxPL cargo drives foam cell formation, endothelial dysfunction, and macrophage activation via LOX-1 receptor stimulation. It also promotes calcification in aortic valve interstitial cells — a mechanism that directly links Lp(a) to calcific aortic stenosis, a connection now confirmed by Mendelian randomization.

Thrombogenicity: Because apo(a) structurally mimics plasminogen, it competes for fibrin binding sites, impairing fibrinolysis and promoting clot persistence. It also disrupts the regulation of tissue plasminogen activator (tPA) and PAI-1, creating a prothrombotic environment that amplifies the consequences of plaque rupture.

Inflammation and OxPL signaling: As the dominant carrier of oxidized phospholipids in plasma, Lp(a) activates inflammatory cascades in the vessel wall — stimulating IL-8 and MCP-1 production, recruiting monocytes, and activating the NLRP3 inflammasome pathway. Elevated OxPL-apoB levels, a direct readout of Lp(a)-bound OxPL, independently predict both MACE and aortic stenosis progression.

This triple mechanism of harm — atherogenic, thrombogenic, and pro-inflammatory — is what distinguishes Lp(a) from LDL and explains why LDL-lowering therapies alone cannot neutralize its risk.

Written in the Genome

Perhaps the most clinically important feature of Lp(a) is its extraordinary heritability. Plasma Lp(a) levels are 80–90% genetically determined, governed almost entirely by the LPA gene on chromosome 6q26–27. This makes Lp(a) one of the most heritable cardiovascular risk factors known to medicine. The practical implication is stark: diet, exercise, and weight loss have negligible impact on Lp(a) levels. Unlike LDL-C, there is no lifestyle intervention that meaningfully moves the needle.

And then there is the statin paradox. Statins upregulate hepatic LDL receptors, but Lp(a) is cleared through an LDL receptor-independent pathway. The result: intensive statin therapy may paradoxically increase Lp(a) by 10–20% by upregulating hepatic apo(a) synthesis. This is not a reason to avoid statins — their LDL-C benefits are unambiguous — but it is a reason to stop assuming that statin-treated patients have their cardiovascular risk fully addressed.

A Global Burden, Unequally Distributed

The epidemiological scale of elevated Lp(a) is staggering and underappreciated. Approximately 1.4 billion people worldwide — roughly 20% of the global population — carry Lp(a) levels above 50 mg/dL (125 nmol/L), making it the most common inherited cardiovascular risk factor in existence. About 10% of the general population has Lp(a) exceeding 100 mg/dL (~250 nmol/L), placing them in a very high cardiovascular risk category.

The distribution is not uniform across populations. Black and African-descent individuals carry Lp(a) levels approximately 2–3 times higher than white Europeans on average. South Asian populations also exhibit disproportionately elevated median Lp(a), contributing to the excess ASCVD risk seen in this group that traditional risk models consistently fail to capture. These ethnic disparities are clinically important — and they are largely invisible when risk is assessed using standard tools calibrated on European cohorts.

The Evidence for Causality Is Ironclad

For years, Lp(a) was treated as an interesting association rather than a causal risk factor. That debate is now settled. Multiple large-scale Mendelian randomization studies — using LPA SNPs as genetic instruments to isolate the effect of lifelong Lp(a) elevation from confounders — have confirmed a causal, dose-dependent relationship between Lp(a) and major adverse cardiovascular events (MACE).

The Copenhagen General Population Study found that Lp(a) above the 99th percentile was associated with a 3-fold increased risk of myocardial infarction and a 2-fold increased risk of ischemic stroke compared to the lowest quartile. Clarke et al., writing in JAMA in 2009, demonstrated that doubling Lp(a) levels increases relative MI risk by approximately 22%. The INTERHEART Study attributed roughly 25% of population-attributable risk for MI globally to elevated Lp(a), independent of standard risk factors. And Mendelian randomization has now confirmed a causal role in calcific aortic stenosis — Lp(a) above 50 mg/dL is associated with a 1.5–1.8-fold increased risk of aortic valve disease requiring intervention.

Critically, all of this risk operates independently of LDL-C. A patient with a well-controlled LDL of 60 mg/dL remains at substantially elevated cardiovascular risk if their Lp(a) is high. This is the clinical reality that the field has been slow to internalize.

Measuring It Correctly — and What the Guidelines Say

Lp(a) can be reported in two units: nmol/L (particle number) or mg/dL (mass). The distinction matters enormously. Because apo(a) isoform size varies between individuals, the commonly used conversion factor of ~2.5 mg/dL per nmol/L is an approximation that introduces significant error at the individual level. The preferred unit for clinical risk assessment — as recommended by the European Atherosclerosis Society (EAS) and ACC/AHA — is nmol/L, using isoform-insensitive assays calibrated against WHO reference material.

The major cardiology societies have progressively strengthened their guidance on Lp(a) testing. The ACC/AHA 2018 guidelines designated Lp(a) ≥50 mg/dL as a "risk-enhancing factor" to be considered when initiating or intensifying statin therapy in intermediate-risk patients. The EAS 2022 consensus went further, calling for at least one lifetime measurement in all adults — noting that Lp(a) above 180 mg/dL (~430 nmol/L) confers a lifetime MACE risk equivalent to heterozygous familial hypercholesterolemia. The Canadian Cardiovascular Society has gone furthest, recommending cascade testing of first-degree relatives when a proband has confirmed elevated Lp(a).

The emerging consensus is clear: universal once-in-a-lifetime screening, analogous to FH detection strategies, is where the field is heading.

The Therapeutic Gap — and the Revolution Underway

Here is where the clinical picture becomes both sobering and genuinely exciting. Current pharmacological options for Lp(a) lowering are limited. Statins don't lower it — they may raise it. PCSK9 inhibitors (evolocumab, alirocumab) achieve a modest 20–30% reduction, with MACE benefit observed in Lp(a)-high subgroups in the FOURIER and ODYSSEY OUTCOMES trials, but this magnitude of reduction is insufficient as a primary Lp(a) strategy. Niacin reduces Lp(a) by 20–40% but failed to improve cardiovascular outcomes in the AIM-HIGH and HPS2-THRIVE trials, and its toxicity profile limits clinical use. Lipoprotein apheresis — the most effective current option, achieving 60–75% reduction per session — is FDA-cleared for progressive ASCVD with elevated Lp(a), but biweekly sessions, limited access, and cost make it impractical for most patients.

The critical unmet need is stark: no currently available oral pharmacotherapy achieves the >50–80% Lp(a) reduction likely required for meaningful MACE risk reduction at the population level.

That is precisely what makes the emerging RNA-based therapies so transformative. By targeting hepatic LPA mRNA directly, antisense oligonucleotide (ASO) and small interfering RNA (siRNA) technologies are achieving reductions that no prior therapy has approached.

Pelacarsen (TQJ230, Novartis/Ionis), a GalNAc-conjugated ASO, demonstrated 80% Lp(a) reduction in Phase 2 trials with monthly dosing. Its Phase 3 Lp(a)HORIZON trial — enrolling 7,680 high-risk ASCVD patients — is the first trial powered to test whether Lp(a) lowering actually reduces hard cardiovascular events.

Olpasiran (AMG 890, Amgen), a GalNAc-conjugated siRNA, achieved a remarkable 97% Lp(a) reduction sustained for 12 or more weeks after a single dose in the OCEAN(a)-DOSE Phase 2 trial. Its Phase 3 OCEAN(a)-Outcomes trial is underway, with quarterly dosing representing a major adherence advantage.

Zerlasiran (Silence Therapeutics) demonstrated durable >90% reduction with twice-yearly dosing in the SOLSTICE Phase 2 trial. And muvalaplin (AstraZeneca/Ionis) — the first oral small molecule targeting Lp(a), disrupting the intramolecular apo(a) structure — achieved up to 65% reduction in the Phase 2 KRAKEN trial. If validated, an oral agent would transform access and adherence at scale.

Phase 3 outcomes data from Lp(a)HORIZON and OCEAN(a) are expected in 2025–2026. These trials will answer the defining question of the field: does lowering Lp(a) reduce MACE?

What to Do Right Now

While the field awaits those landmark results, clinicians are not without a framework for action. The approach is straightforward: explain without alarming, contextualize Lp(a) within the patient's overall risk profile, and aggressively manage every modifiable risk factor that co-exists with it. Aggressive LDL-C lowering (targeting <55–70 mg/dL in high-risk patients), blood pressure control, smoking cessation, and glycemic optimization all reduce the residual ASCVD risk that accompanies elevated Lp(a). In patients with very elevated Lp(a) and established ASCVD, PCSK9 inhibitor therapy is reasonable — even modest 20–30% Lp(a) lowering, compounded with LDL-C reduction, yields meaningful benefit.

Patients with Lp(a) ≥70 mg/dL or ≥150 nmol/L may qualify for the landmark outcome trials currently enrolling — and actively referring eligible patients is itself a form of clinical action. Cascade testing of first-degree relatives is strongly advisable when a proband has Lp(a) above 125 nmol/L, given the 80–90% heritability. And because Lp(a) is genetically stable, one baseline measurement is sufficient in most patients — over-testing increases anxiety without generating actionable information.

The Bottom Line

Lp(a) is not a niche biomarker for subspecialty lipidologists. It is a causal, dose-dependent, genetically determined cardiovascular risk factor affecting roughly one in five people globally — and it is invisible to the standard risk models and therapies that dominate clinical practice. The science establishing its harm is now ironclad. The tools to measure it correctly exist. The guidelines are converging on universal screening. And within the next two to three years, the first approved therapies capable of meaningfully lowering it may reach clinical practice.

As the EAS Consensus Panel put it in 2022: "Lp(a) represents the largest unaddressed monogenic cardiovascular risk factor in clinical medicine. The next three years will determine whether we can finally intervene on it effectively."

The time to start measuring it — and talking to patients about it — is now.